Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Neurocrine hands back 2 CNS gene therapy programs to Voyager
Neurocrine handed back two discovery-stage gene therapy programs to Voyager, although the companies’ wider CNS-focused collaboration remains on track.
James Waldron
May 7, 2025 7:30am
Verily nets $14.7M MJFF grant for personalized Parkinson's data
Apr 30, 2025 9:00am
Servier severing forces OPM to make 'drastic choices' to adapt
Apr 4, 2025 9:05am
Cerevance fails phase 2 trial in early, untreated Parkinson's
Apr 1, 2025 10:19am
Newronika nets CE mark for adaptive DBS in Parkinson's disease
Mar 26, 2025 10:36am
Hologen AI commits $430M to MeiraGTx Parkinson's gene therapy
Mar 13, 2025 10:51am
